NCT01107717 - Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM | Biotech Hunter

Enrollment

318

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions

Diabetes

Interventions

DRUG

metformin\pioglitazone\exenatide

metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%

DRUG

metformin, glyburide and glargine

subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%

Trial Locations (1)

78229-3900

Texas Diabetes Institute, San Antonio